Report covers Silexion Therapeutics (NASDAQ:SLXN), a disruptive player in the precision oncology space, developing innovative RNAi therapies targeting KRAS-driven cancers, highlighting the company's impressive clinical achievements and unique approach alongside industry drivers including the increasing M&A activity in the space Silexion Therapeutics (NASDAQ:SLXN) has emerged an intriguing yet under the radar player in the precision oncology space, focusing on developing innovative RNA interference (RNAi) therapies for KRAS-driven cancers. As a recently de-SPACed company following its merger with Moringa Acquisition Corp (NASDAQ:MACA), Silexion presents an interesting opportunity in the rap

MODI'IN, Israel and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Silexion Therapeutics Ltd. ("Silexion"), a clinical-stage, oncology-focused biotechnology company and Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a publicly-traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination") with Biomotion Sciences (the "combined company"), a recently formed entity. The combined company's name is changing from Biomotion Sciences to "Silexion Therapeutics Corp", and its ordinary shares and warrants are expected to begin trading on Nasdaq under the tickers "SLXN" and "SLXNW", respectively, on August 16

                                       Silexion's first generation product, Loder™, successfully tested in a multinational Phase 2a clinical trial in patients with non-resectable pancreatic cancer which harbors an oncogene believed to be a major driver of the cancer In combination with chemotherapy, Loder resulted in a median overall survival (OS) advantage of 9.3 months over chemotherapy alone (22.7 vs 13.4 months) Modi'in, Israel and New York, New York, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa"), a special purpose acquisition company, today announced it has entered into a business combination agreement with Silexion Ltd. ("Silexion"), a cli

New York, NY, Aug. 15, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa" or the "Company") announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2023 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on August 16, 2023 (the "Extraordinary Meeting") for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination (the "Extension") from August 19, 2023 (the "Current Termination Date") to August 19, 2024 or such earlier date as may be determ

New York, NY, Feb. 07, 2023 (GLOBE NEWSWIRE) --  Moringa Acquisition Corp (NASDAQ:MACA) ("Moringa" or the "Company") announced today that, the extraordinary general meeting in lieu of the 2022 annual general meeting of shareholders of the Company (the "Extraordinary Meeting"), originally scheduled to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on February 7, 2023, was convened and then adjourned, without conducting any business, to recommence at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on February 9, 2023 as a virtual meeting via live webcast at https://www.cstproxy.com/moringaac/2023. The Extraordinary Meeting is being held for the purpose of considering a

New York, NY, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NASDAQ:MACA)  ("Moringa" or the "Company") announced today that, in connection with its previously announced extraordinary general meeting in lieu of the 2022 annual general meeting of shareholders of the Company to be held at 9:00 a.m. Eastern Time/4:00 p.m. local (Israel) time on February 7, 2023 (the "Extraordinary Meeting") for the purpose of considering and voting on, among other proposals, a proposal to extend the date by which the Company must consummate an initial business combination (the "Extension") from February 19, 2023 (the "Original Termination Date") to August 19, 2023 or such earlier date as may be

Holisto's advanced AI technology addresses the fragmented and complex travel booking market, providing consumers with a more affordable and personalized offeringSince commercial product launch in Q2 2020, Holisto's online booking platform has gained significant market acceptanceTransaction enables Holisto to scale its customer acquisition and brand awareness strategy Rishon Le'Zion, Israel and New York, New York, June 13, 2022 (GLOBE NEWSWIRE) -- Holisto Ltd, a technology based online travel booking platform ("Holisto" or the "Company"), and Moringa Acquisition Corp (NASDAQ:MACA, "Moringa"))), a special purpose acquisition company, today announced they have entered into a busines

NEW YORK, NY, April 05, 2022 (GLOBE NEWSWIRE) -- Moringa Acquisition Corp (NasdaqCM: MACA, MACAU and MACAW) (the "Company") announced that it filed its annual report on Form 10-K for the year ended December 31, 2021 with the Securities and Exchange Commission on March 31, 2022. Copies of the annual report and other filings are available online through the Company's website, https://www.moringaac.com/, or by accessing the Securities and Exchange Commission's website, www.sec.gov. Copies may also be obtained from the Company, Attn: Gil Maman, 250 Park Avenue, 7th Floor, New York, NY 11040, or by email: [email protected]. About Moringa Acquisition Corp Moringa Acquisition Corp was f

JERUSALEM, March 21, 2022 /PRNewswire/ -- Alpha Tau Medical Ltd. (NASDAQ:DRTS), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced the appointment of Ms. Ruth (Ruti) Alon to its Board of Directors, effective immediately. "We are pleased to welcome Ruti as the newest member of our Board of Directors," said Uzi Sofer, Chief Executive Officer and Chairman of Alpha Tau. "Ruti's extensive knowledge and experience advising healthcare companies through financial and strategic operations will be a tremendous asset to the Company. We are eager to have her on board and benefit from her insights into our corporate and clinical plan as we grow the Company." Ruti